Annual Report

Overview

The report presents Shield Therapeutics' 2024 growth, including $32.2M in net revenues, 146% growth over 2023, and $29.3M in net ACCRUFER revenues. It highlights Health Canada approval, a successful pediatric pivotal trial, and full recruitment of the China Phase 3 study. The Group reported 63 staff at 31 December 2024 and continued working toward cash-flow positivity by the end of 2025.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services